| Year |
Citation |
Score |
| 2024 |
Godet I, Oza HH, Shi Y, Joe NS, Weinstein AG, Johnson J, Considine M, Talluri S, Zhang J, Xu R, Doctorman S, Mbulaiteye D, Stein-O'Brien G, Kagohara LT, Santa-Maria CA, et al. Hypoxia induces ROS-resistant memory upon reoxygenation in vivo promoting metastasis in part via MUC1-C. Nature Communications. 15: 8416. PMID 39341835 DOI: 10.1038/s41467-024-51995-2 |
0.602 |
|
| 2023 |
Joe NS, Wang Y, Oza HH, Godet I, Milki N, Riggins GJ, Gilkes DM. Mebendazole Treatment Disrupts the Transcriptional Activity of Hypoxia-Inducible Factors 1 and 2 in Breast Cancer Cells. Cancers. 15. PMID 36831670 DOI: 10.3390/cancers15041330 |
0.652 |
|
| 2022 |
Joe NS, Godet I, Milki N, Ain NUI, Oza HH, Riggins GJ, Gilkes DM. Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness. Breast Cancer Research : Bcr. 24: 98. PMID 36578038 DOI: 10.1186/s13058-022-01591-3 |
0.647 |
|
| 2021 |
Joe NS, Hodgdon C, Kraemer L, Redmond KJ, Stearns V, Gilkes DM. A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases. Npj Breast Cancer. 7: 121. PMID 34521857 DOI: 10.1038/s41523-021-00326-5 |
0.719 |
|
| 2019 |
Williamson T, Mendes TB, Joe N, Cerutti JM, Riggins GJ. Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer. Endocrine-Related Cancer. PMID 31846433 DOI: 10.1530/ERC-19-0341 |
0.505 |
|
| Show low-probability matches. |